Market capitalization | $813.59m |
Enterprise Value | $1.02b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.60 |
P/S ratio (TTM) P/S ratio | 3.66 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 29.88% |
Revenue (TTM) Revenue | $222.55m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
6 Analysts have issued a Xeris Pharmaceuticals Inc forecast:
6 Analysts have issued a Xeris Pharmaceuticals Inc forecast:
Mar '25 |
+/-
%
|
||
Revenue | 223 223 |
30%
30%
|
|
Gross Profit | 172 172 |
31%
31%
|
|
EBITDA | -9.94 -9.94 |
69%
69%
|
EBIT (Operating Income) EBIT | -22 -22 |
50%
50%
|
Net Profit | -45 -45 |
30%
30%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL.
Head office | United States |
CEO | John Shannon |
Employees | 394 |
Founded | 2005 |
Website | www.xerispharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.